# UPMC OPTIMISE-C19 Trial, a COVID-19 Study

> **NCT04790786** · PHASE4 · TERMINATED · sponsor: **Erin McCreary** · enrollment: 4571 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Lilly Bamlanivimab
- **BIOLOGICAL:** Regeneron Casirivimab + Imdevimab
- **BIOLOGICAL:** Lilly Bamlanivimab + Etesevimab
- **BIOLOGICAL:** Sotrovimab
- **BIOLOGICAL:** Bebtelovimab

## Key facts

- **NCT ID:** NCT04790786
- **Lead sponsor:** Erin McCreary
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-10
- **Primary completion:** 2022-06-16
- **Final completion:** 2022-06-16
- **Target enrollment:** 4571 (ACTUAL)
- **Why stopped:** Emergency Use Authorizations for monoclonal antibodies withdrawn
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790786, "UPMC OPTIMISE-C19 Trial, a COVID-19 Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04790786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*